Drug Profile


Alternative Names: Intelence; R165335; TMC-125

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen-Cilag; Xian-Janssen
  • Class Antiretrovirals; Pyridazines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 10 Mar 2015 No recent reports on development identified - Phase-II for HIV-1 infections (Combination therapy, Treatment-naive) in USA, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Romania, Russia, Spain, Switzerland and United Kingdom (PO)
  • 01 Oct 2014 Biomarkers information updated
  • 16 Nov 2012 Committee for Medicinal Products for Human Use recommends approval of Etravirine for HIV-1 infections (combination therapy, in children, in adolescents, treatment-experienced patients) in EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top